About Stark Oncology Consulting
James J. Stark, MD, FACP, is the founder of Stark Oncology Consulting, a venture designed to assist individuals and companies seeking expert testimony and medical consultation related to oncology. Dr. Stark founded Stark Oncology Consulting in 2011.
For over three decades, Dr. James Stark has worked as a practitioner and instructor in the field of medical oncology. His expertise in the diagnosis, progress, and treatment of various cancers have made him a much sought-after expert witness in area malpractice trials. If you work for a law office, insurance firm, or medical company, Dr. Stark is available for concise oncology consultation services to assist plaintiffs and defendants in medical litigation cases across the United States.
Plants as the Source of New Cancer Chemotherapy Drugs
Posted on 27 May, 2021
Dr. Stark just finished a review of plants as the source of new cancer drugs. He gave this talk to…
New Lung Cancer Drug
Posted on 26 May, 2021
The treatment of non-small-cell lung cancer has undergone a revolution in the last ten years with the development of drugs…
Blog & Articles
- Lung Cancer 2014: The New Paradigm; then on to 2020 Posted on 20 Aug, 2014
- Dr. Stark on Causation in Cancer Cases Posted on 21 Oct, 2013
- A Blood Clotting Catastrophe: the denoument Posted on 22 Jun, 2013
- The most common reasons for Breast Cancer lawsuits are failure to interpret a mammogram properly and failure to evaluate a woman’s complaint of a lump in her breast.
- Colon cancer is among the slowest growing common adult tumors with characteristics that make the missed diagnosis of colon cancer an ideal lawsuit for a plaintiff.
- The overall mortality of lung cancer is 90%. By the time the plaintiff complains of coughing up blood or chest pain it is almost always too late to effect a cure.
- Not every bad result associated with cancer chemotherapy is caused by negligent care. Mediports and similar devices have a simple structure but one that can fail without warning.
- From a litigation perspective, it was clear by 2011 that failure to offer colorectal or breast cancer screening is negligent. The same cannot be said for the much rarer syndromes.
- When the mathematics is understood and the calculations are performed properly there is a role for the use of doubling time in causation arguments.